The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery

Publication date: 6 July 2017
Source:Cell Stem Cell, Volume 21, Issue 1
Author(s): Gary Gintant, Bernard Fermini, Norman Stockbridge, David Strauss
Nonclinical studies of drug effects with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and efficacy. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons from the cardiac field that also apply to drug studies with other stem cell-based assays.

Teaser

Nonclinical studies of drug effects with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide new possibilities for evaluating drug safety and efficacy. The Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm provides lessons from the cardiac field that also apply to drug studies with other stem cell-based assays.


http://ift.tt/2su49PG